256 related articles for article (PubMed ID: 31313716)
21. Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy.
Massari F; Di Nunno V; Gatto L; Santoni M; Schiavina R; Cosmai L; Brunocilla E; Ardizzoni A; Porta C
Target Oncol; 2018 Dec; 13(6):705-714. PubMed ID: 30324488
[TBL] [Abstract][Full Text] [Related]
22. The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update.
Gurram S; Al Harthy M; Ball MW
Discov Med; 2020; 29(158):191-199. PubMed ID: 33007194
[TBL] [Abstract][Full Text] [Related]
23. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
[TBL] [Abstract][Full Text] [Related]
24. Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift?
Dariane C; Timsit MO; Méjean A
Bull Cancer; 2018 Dec; 105 Suppl 3():S229-S234. PubMed ID: 30595151
[TBL] [Abstract][Full Text] [Related]
25. Cytoreductive nephrectomy in metastatic renal cell carcinoma.
Margulis V; Matin SF; Wood CG
Curr Opin Urol; 2008 Sep; 18(5):474-80. PubMed ID: 18670270
[TBL] [Abstract][Full Text] [Related]
26. Up-front Targeted Therapy Prior to Cytoreductive Nephrectomy in Treatment-Naive Patients With Metastatic Renal Cell Carcinoma.
Agarwal N; Shuch B; Pal SK
JAMA Oncol; 2016 Oct; 2(10):1273-1274. PubMed ID: 27254305
[No Abstract] [Full Text] [Related]
27. Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors.
Biles MJ; Patel HD; Allaf ME
Urol Clin North Am; 2020 Aug; 47(3):359-370. PubMed ID: 32600537
[TBL] [Abstract][Full Text] [Related]
28. Cytoreductive nephrectomy: future directions.
Margulis V; Hakimi AA
Curr Opin Urol; 2019 Sep; 29(5):540-541. PubMed ID: 31305272
[No Abstract] [Full Text] [Related]
29. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis.
Petrelli F; Coinu A; Vavassori I; Cabiddu M; Borgonovo K; Ghilardi M; Lonati V; Barni S
Clin Genitourin Cancer; 2016 Dec; 14(6):465-472. PubMed ID: 27138461
[TBL] [Abstract][Full Text] [Related]
30. Role of cytoreductive nephrectomy in renal cell carcinoma.
Chiong E; Wood CG; Margulis V
Future Oncol; 2009 Aug; 5(6):859-69. PubMed ID: 19663735
[TBL] [Abstract][Full Text] [Related]
31. The role and timing of cytoreductive nephrectomy in the immunotherapy era.
Wong ECL; Kapoor A
Eur Urol Focus; 2020 Jan; 6(1):7-8. PubMed ID: 30824380
[TBL] [Abstract][Full Text] [Related]
32. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma.
Hsiang WR; Kenney PA; Leapman MS
Curr Oncol Rep; 2020 Mar; 22(4):35. PubMed ID: 32170461
[TBL] [Abstract][Full Text] [Related]
33. Considerations for the Next Clinical Trial Evaluating the Role of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
Kim HL; Mayerson E; Lara PN; Messing E; Tangen C; Shuch BM; Vaishampayan U
Eur Urol Focus; 2019 Nov; 5(6):927-929. PubMed ID: 31103605
[TBL] [Abstract][Full Text] [Related]
34. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
35. Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy.
Song Y; Du CX; Zhang W; Sun YK; Yang L; Cui CX; Chi YB; Shou JZ; Zhou AP; Li CL; Ma JH; Wang JW; Sun Y
Chin Med J (Engl); 2016 Mar; 129(5):530-5. PubMed ID: 26904986
[TBL] [Abstract][Full Text] [Related]
36. Editorial Comment to Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era.
Bigot P; Lebdai S; Azzouzi AR
Int J Urol; 2015 Aug; 22(8):740-1. PubMed ID: 26012629
[No Abstract] [Full Text] [Related]
37. Cytoreductive nephrectomy in the era of targeted therapies: a review.
Pindoria N; Raison N; Blecher G; Catterwell R; Dasgupta P
BJU Int; 2017 Sep; 120(3):320-328. PubMed ID: 28371084
[TBL] [Abstract][Full Text] [Related]
38. The role of cytoreductive nephrectomy in the immuno-oncological therapy era.
Magee DE; Helstrom E; Kutikov A
Curr Opin Urol; 2023 Mar; 33(2):136-141. PubMed ID: 36710594
[TBL] [Abstract][Full Text] [Related]
39. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.
Verzoni E; Ratta R; Grassi P; Salvioni R; Stagni S; Montone R; Fucà G; Cappelletti V; Reduzzi C; De Giorgi U; Procopio G
Tumori; 2018 Oct; 104(5):401-405. PubMed ID: 29192741
[TBL] [Abstract][Full Text] [Related]
40. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
Chery LJ; Karam JA; Wood CG
Clin Adv Hematol Oncol; 2016 Sep; 14(9):696-703. PubMed ID: 27673288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]